| Literature DB >> 35061138 |
Sahib S Khalsa1,2, Laura A Berner3, Lisa M Anderson4.
Abstract
PURPOSE OF REVIEW: Abnormal interoception has been consistently observed across eating disorders despite limited inclusion in diagnostic conceptualization. Using the alimentary tract as well as recent developments in interoceptive neuroscience and predictive processing as a guide, the current review summarizes evidence of gastrointestinal interoceptive dysfunction in eating disorders. RECENTEntities:
Keywords: Anorexia nervosa; Avoidant/restrictive food intake disorder; Binge-eating disorder; Bulimia nervosa; Digestion; Interoceptive awareness
Mesh:
Year: 2022 PMID: 35061138 PMCID: PMC8898253 DOI: 10.1007/s11920-022-01318-3
Source DB: PubMed Journal: Curr Psychiatry Rep ISSN: 1523-3812 Impact factor: 5.285
Recent approaches relevant for investigating gastrointestinal interoception in eating disorders
| Approach | Intended effect | Sensory transduction mechanism |
|---|---|---|
| Vibrating capsule (Vibrant Inc.) [ | Provide mechanosensory stimulation to gut afferents, to measure conscious sensation | Unknown; likely stimulates mechanoreceptors (e.g., voltage-gated, PIEZOs) |
| Gelesis 100 hydrogel capsule (Gelesis Inc.) [ | Increase volume and elasticity of the stomach and small intestine contents, to generate the feeling of fullness | Unknown; non-aggregating cross-linked cellulose and citric acid particles increase in volume after absorbing water, creating a nearby mass effect |
| SmartPill™ Motility testing system (Medtronic Inc.) [ | Measure pressure, pH and temperature throughout the GI tract, providing information on gastric emptying and GI transit time | None |
| High-density electrogastrogram [ | Estimate direction and speed of gastric slow waves following caloric stimulation | None |
| Gut-brain synchrony via resting state EGG-fMRI [ | Identify the “gastric network” defined by correlated activity between stomach and brain | Unknown |
| Semaglutide (Wegovy™) [ | Chronic weight management for overweight or obese individuals | Unknown; glucagon-like peptide-1 (GLP1) receptor agonist resulting in lower blood glucose levels. GLP1 receptors are located in the brain in interoception- and reward-relevant regions including the nucleus accumbens, ventral tegmental area, hypothalamus, and brainstem (nucleus tractus solitarius; NTS) |
| Erythromycin [ | Induce gastric contractions, hunger signals, and food intake | Motilin receptor agonist |
| Gymnema sylvestre [ | Eliminate sweet taste perception | Block sucrose receptors in mouth or block intestinal sucrose absorption |
| 16-h fast [ | Remove stomach contents and elicit hunger hormonal signaling cascade | Modulate food reward-motivation neurocircuitry |
Fig. 1Phases of food consumption from foraging to expulsion. Starting with the cephalic phase, each phase involves predictive processing and likely has a dedicated gastrointestinal interoceptive neurocircuitry. Studies of interoception in eating disorders have preferentially focused on the cephalic rather than the ingestive phase of the digestive process. See text for details
Future research questions
| • What is the relationship between microbiome-host interactions and the trafficking of interoceptive signals in the gut? How does this crosstalk influence eating disorder expression? |
| • How do metabolic-, energetic-, and exercise-related genetic markers for eating disorders influence the neural circuits of interoception? |
| • How do gut predictions and prediction errors at each stage of food consumption influence the development and/or maintenance of eating disorder symptoms? Do increased gut prediction error signals promote restriction, while decreased gut prediction error signals promote binge eating and purging? |
| • How do the neural circuits of gastrointestinal interoception interact with those implicated in reward, emotion regulation, habitual behavior, and cognitive control? |
| • To what extent does the neurocircuitry underlying eating disorders overlap with that of functional gastrointestinal disorders? |
| • Which interoceptive targets within the gastrointestinal system show the most promise for early identification, prevention, or treatment of eating disorders? |